Oracle launches unified health data exchange console
Travere Therapeutics Inc. (TVTX) stock reached a 52-week high of 25.33 USD, marking a significant milestone for the $1.9 billion market cap company. According to InvestingPro analysis, the stock appears to be trading above its Fair Value, with analysts setting price targets between $20 and $47. Over the past year, the stock has experienced a remarkable increase of 76.8%, reflecting strong investor confidence and potential positive developments within the company. This upward trajectory highlights Travere Therapeutics’ robust performance in the biotechnology sector, supported by impressive 88% revenue growth over the last twelve months. InvestingPro data reveals the stock’s RSI suggests overbought territory - one of 12 exclusive ProTips available for this stock. The stock’s recent high emphasizes its growth momentum and the market’s optimistic outlook on its future prospects, with analysts maintaining a strong buy consensus.
In other recent news, Travere Therapeutics has made several notable announcements. The U.S. Food and Drug Administration (FDA) has decided that an advisory committee is no longer necessary for the review of Travere’s drug FILSPARI, aimed at treating focal segmental glomerulosclerosis (FSGS). The supplemental New Drug Application for this drug remains under review, with a target action date set for January 13, 2026. Additionally, the FDA has approved updated monitoring requirements for FILSPARI, reducing liver function monitoring frequency and removing the embryo-fetal toxicity monitoring requirement.
In terms of analyst actions, H.C. Wainwright has raised its price target for Travere Therapeutics to $47, maintaining a Buy rating, following the FDA’s approval of the updated REMS labeling for FILSPARI. Conversely, Stifel has lowered its price target to $20 while maintaining a Hold rating, citing regulatory uncertainty around the FSGS approval process. Furthermore, new long-term data from the Phase 1/2 COMPOSE study was presented, showing significant reductions in homocysteine and methionine levels in patients treated with pegtibatinase. These developments reflect ongoing changes and assessments for Travere Therapeutics in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.